Though Abraxane (paclitaxel) is now part of Celgene Corp. 's growing oncology portfolio, you don't need Celgene stock to invest in its newest product, a reformulation of the generic chemotherapy
Although scientific and clinical interest in molecular diagnostics is at an all-time high, companies are still struggling to find the right business model for the field. Qiagen NV 's recent acquisi
After years of confusion and stagnation, the field of cancer biomarker diagnostics seems to be progressing, even as huge challenges remain. Investors are alert but cautious. After years of false hope
In this issue, we present another installment of our quarterly review of dealmaking—for April-June 2004. Our data comes from Windhover's Strategic Transactions Database , which covers deal activity w